Patents by Inventor John van Drie

John van Drie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of GLI1 as therapeutic agents
    Patent number: 12209092
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 28, 2025
    Assignee: New York University
    Inventors: William J. Greenlee, John Van Drie, Xinyan Huang, James Salzer, Nadim Shohdy
  • INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS
    Publication number: 20220009935
    Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.
    Type: Application
    Filed: November 19, 2019
    Publication date: January 13, 2022
    Inventors: William J. GREENLEE, John VAN DRIE, Xinyan HUANG, James SALZER, Nadim SHOHDY
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20080045480
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: May 22, 2007
    Publication date: February 21, 2008
    Inventors: Luc Farmer, Robert Perni, Janos Pitlik, John van Drie
  • Inhibitors of serine proteases, particular HCV NS3-NS4A protease
    Publication number: 20070292933
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: July 23, 2007
    Publication date: December 20, 2007
    Inventors: Janos Pitlik, Kevin Cottrell, Luc Farmer, Robert Perni, Lawrence Courtney, John van Drie, Mark Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20050137139
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: September 7, 2004
    Publication date: June 23, 2005
    Inventors: Robert Perni, John Court, Shawn Britt, Janos Pitlik, John van Drie
  • Bridged bicyclic serine protease inhibitors
    Patent number: 6909000
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: June 21, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie
  • Processes for producing optimized pharmacophores
    Publication number: 20050049794
    Abstract: The present invention relates to processes for producing an optimized pharmacophore for a target protein. The present invention also relates to processes for identifying compounds having an affinity to a target protein. The present invention also relates to processes for designing a ligand for a target protein using the optimized pharmacophore of the present invention. The present invention also provides a computer for use in designing a ligand for a target protein using the optimized pharmacophore of the present invention.
    Type: Application
    Filed: April 29, 2004
    Publication date: March 3, 2005
    Inventors: John van Drie, Jeffrey Peng
  • Bridged bicyclic serine protease inhibitors
    Publication number: 20030119752
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: July 11, 2002
    Publication date: June 26, 2003
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie